Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

NCT00643617 is registered in ClinicalTrials.gov with Accuray Incorporated as lead sponsor.

NCT NCT00643617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00643617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Lead sponsor
Accuray Incorporated
Phase
Not applicable
Overall status
Completed
Start date
October 22, 2007
Completion date
April 7, 2022
Enrollment
307 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate, prostate cancer, prostate neoplasms, prostatic cancer, prostatic neoplasms